Physiologic Assessment of Microvascular Function in Patients With Cardiac Amyloidosis

Cardiac Amyloidosis Clinical Trial

Official title:

Physiologic Assessment of Microvascular Function in Patients With Cardiac Amyloidosis: Prospective Registry and Pilot Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02798705
• Other study ID #: AMYL2016-04-122
• Status: Recruiting
• Start date: May 2016
• Est. completion date: December 2025

Study information

• Verified date: November 2023
• Source: Samsung Medical Center
• Contact: Joo Myung Lee, MD, MPH, PhD
• Phone: 82-2-3410-1246
• Email: drone80[@]hanmail.net
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The aim of the study is to evaluate coronary flow reserve (CFR), index of microcirculatory resistance (IMR), and proportion of overt microvascular disease, defined as depressed CFR as well as elevated IMR in patients with cardiac amyloidosis. The second objective of this study is to compare results of non-invasive test including serum light chain amount, Doppler echocardiography with 2D strain, and cardiac perfusion MRI. The third object of this study is to evaluate the association between physiologic indices and pathologically measured percent area involvement of interstitium.

Description:

Amyloidosis is rare systemic disorder characterized by the extracellular deposition of misfolded protein in various organ system, including heart. Among the several types of amyloid fibrils, the light chain and transthyretin amyloid proteins most commonly affect the heart.

Cardiac amyloid deposits result in increased ventricular wall thickness and produce a restrictive cardiomyopathy presenting primarily as biventricular congestive heart failure. Anginal symptoms and signs of ischemia have been reported in some patients with cardiac amyloidosis without obstructive epicardial coronary artery disease (CAD). Autopsy studies have shown amyloid deposits around and between cardiac myocytes in the interstitium, the perivascular regions, and the media of intramyocardial coronary vessels. Amyloidosis is thus a prime example of a disorder with the potential to cause coronary microvascular dysfunction via 3 major mechanisms: (1) structural (amyloid deposition in the vessel wall causing wall thickening and luminal stenosis), (2) extravascular (extrinsic compression of the microvasculature from perivascular and interstitial amyloid deposits and decreased diastolic perfusion), and (3) functional (autonomic and endothelial dysfunction).

Previous basic research presented that adipose arteriole or atrial coronary arterioles showed endothelial dysfunction even after brief exposure to physiologic amounts of light chain, and also showed increased oxidative stress, reduced NO bioavailability, and peroxynitrite production. All these previous evidences imply that coronary microvascular dysfunction and subsequent global ischemic insult can be precursor of overt diastolic or systolic dysfunction in patients with cardiac amyloidosis.

However, there have only 1 study which evaluated microvascular function in vivo using N13-ammonium positron emission tomography (PET). In that study, Dorbala et al. demonstrated that amyloidosis patients showed depressed global resting myocardial blood flow (MBF), stress MBF, and CFR and higher minimal coronary vascular resistance, compared with patients with left ventricular hypertrophy. However, low availability, high cost, and limited resolution of N13 ammonium PET precludes the generalizability of the results.

Since thermodilution-derived coronary flow reserve and index or microcirculatory reserve using pressure-temperature wire has been well validated prognostic index in assessment of patients with coronary artery disease or functionally insignificant epicardial coronary stenosis, invasive physiologic assessment might more specifically assess macro- and microvascular function in patients with cardiac amyloidosis. Moreover, adding physiologic measurement in the current frame in diagnosis of cardiac amyloidosis might enhance risk stratification of patients.

Therefore, the current study will perform physiologic assessment including fractional flow reserve, coronary flow reserve, and index of microcirculatory resistance in patients with cardiac amyloidosis, and explore correlation among the physiologic indices and conventional measurements of echocardiography, perfusion MRI, serum light chain amount, or NT-proBNP. In addition, the differences of physiologic indices according to disease severity of cardiac amyloidosis, which measured by endomyocardial biopsy findings will be also explored. Since there was no previous study which performed invasive physiologic assessment in amyloidosis patients, this study will be performed as pilot study. Target sample size will be at least 30 patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 2025
• Est. primary completion date: April 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Subject age 18-85 years old

• Patients with confirmed cardiac amyloidosis by heart biopsy

• Patients with confirmed amyloidosis by biopsy other than heart and evidence of cardiac involvement in echocardiography

• Patients who underwent invasive physiologic assessment within 3 months from diagnosis of primary disease

Exclusion Criteria:

• Patients with cardiogenic shock

• Patients with unstable vital sign that precludes coronary angiography

• Patients with major bleeding in last 3 months

• Patients with active bleeding

• Patients with coagulopathy

• Patients with severe valvular heart disease

• Patients who refused to provide informed consent

Related Conditions & MeSH terms

• Amyloidosis
• Cardiac Amyloidosis

Locations

Country	Name	City	State
Korea, Republic of	Samsung Medical Center	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Samsung Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	all-cause mortality	Comparison of all-cause mortality in amyloidosis patients with or without microvascular disease	2 Years
Secondary	Correlation between IMR and echocardiographic parameters	Correlation between IMR and echocardiographic parameters (E/E', LV ejection fraction, etc.)	within 3 months of diagnosis
Secondary	Correlation between IMR and serum biochemicalmarkers	Correlation between IMR and serum biochemicalmarkers (troponin T, NT-proBNP, serum free light chain)	within 3 months of diagnosis
Secondary	Distribution of CFR or IMR according to pathologic severity of myocardial involvement	Distribution of CFR or IMR according to pathologic severity of myocardial involvement (Percent amyloid load)	within 3 months of diagnosis
Secondary	Comparison of CFR or IMR value in amyloidosis patient with or without relative perfusion defect in myocardial perfusion imaging (ex> adenosine-SPECT or perfusion MRI)		within 3 months of diagnosis
Secondary	Comparison of CFR or IMR value in different type of amyloidosis (AL type, hereditary type, AA type, senile type)		within 3 months of diagnosis
Secondary	Comparison of CFR or IMR value in amyloidosis patient according to current staging by Troponin T, NT-proBNP and free light chain difference		within 3 months of diagnosis
Secondary	Optimal cut-off values of physiologic indices (CFR, IMR) for prediction of all-cause mortality		2 Years
Secondary	Association between physiologic indices and pathologically measured percent area involvement in myocardial interstitium		within 3 months of diagnosis